NEWS HIGHLIGHTS
Published Studies Related to Timoptic (Timolol Ophthalmic)
Effect of timolol on refractive outcomes in eyes with myopic regression after
laser in situ keratomileusis: a prospective randomized clinical trial. [2012]
(length 4 to 8) was used for treatment allocation... CONCLUSIONS: Timolol application is effective for the treatment of myopic
Twenty-four-hour intraocular pressure control with latanoprost-timolol-fixed combination versus bimatoprost in patients who switched from timolol. [2011.10]
PURPOSE: To evaluate bimatoprost versus latanoprost and timolol fixed combination (LTFC) over the 24-hour diurnal curve in patients who switched from timolol... CONCLUSIONS: The LTFC and bimatoprost therapies were equally effective in maintaining IOP at lower levels during the 24-hour period in patients who switched from timolol therapy. Adverse events were more frequent with bimatoprost therapy.
Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. [2011.09]
PURPOSE: The purpose of this study is to compare the safety and intraocular pressure (IOP)-lowering efficacy of travoprost/timolol in a benzalkonium chloride (BAK)-free fixed combination preserved with polyquaternium-1 (TRA/TIM BAK-free), with travoprost/timolol-fixed combination preserved with BAK (TRA/TIM), in patients with open-angle glaucoma or ocular hypertension... CONCLUSION: Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy. No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.
Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension. [2011.08.19]
BACKGROUND: A noninferiority trial was conducted to evaluate the efficacy of a single evening dose of fixed-combination latanoprost 50 mug/mL and timolol 0.5 mg/mL (Xalacom(R); LTFC), in Chinese patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH) who were insufficiently controlled on beta-blocker monotherapy or beta-blocker-based dual therapy... CONCLUSIONS: A single evening dose of LTFC was at least as effective as the unfixed combination of latanoprost in the PM and timolol in the AM in reducing IOP in Chinese subjects with POAG or OH whose IOP was insufficiently reduced with beta-blocker monotherapy or beta-blocker-based dual therapy. LTFC is an effective and well tolerated once-daily treatment for POAG and OH.
Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension. [2011.07]
BACKGROUND: To compare the efficacy and safety of timolol 0.5% versus brinzolamide 1.0% when added to travoprost monotherapy in patients with primary open-angle glaucoma or ocular hypertension... CONCLUSION: Both adjunctive combinations moderately reduced IOP in patients inadequately controlled with travoprost monotherapy, with timolol being slightly stronger 8 hours after instillation. Adjunctive treatment with brinzolamide and travoprost may be an alternative for patients not tolerant or not responsive to treatment with timolol and travoprost.
Clinical Trials Related to Timoptic (Timolol Ophthalmic)
Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma [Recruiting]
Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops [Not yet recruiting]
Effect of Xalacom® (Latanoprost/Timolol) and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular Hypertension [Recruiting]
Glaucoma is one of the most common causes of blindness in the industrialized nations. For a
long time glaucoma has been defined as a disease in which high intraocular pressure (IOP)
leads to irreversible optic disc damage and subsequent visual field loss. However, recent
investigations show that IOP is not the only factor that is involved in the glaucomatous
process leading to retinal ganglion cell death. The role of vascular factors in the
pathogenesis of glaucoma has recently received much attention based on animal experiments
and epidemiological studies. The main focus of glaucoma is still directed towards a decrease
in IOP. There is, however, also considerable interest whether antiglaucoma drugs influence
ocular perfusion. Although measurement of ocular blood flow is still difficult, a number of
innovative techniques have been realized which cover different aspects of ocular perfusion.
In the present study Xalacom® (latanoprost/timolol) and the fixed combination of Combigan®
(brimonidine/timolol) will be compared with respect to their IOP lowering efficacy as well
as their ocular hemodynamic effects.
Timolol Option for Ulcerated Hemangiomas (TOUCH Trial) [Recruiting]
The purpose of this study is to determine whether Timolol 0. 5% Gel Forming Solution is safe
and effective in promoting wound healing of infantile ulcerated hemangiomas compared with
standard conservative management with topical antibiotic.
Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5% [Not yet recruiting]
The purpose of this study is to evaluate the feasibility of rapid evaluation and
administration of ophthalmic Timolol maleate in the treatment of non-arteritic anterior
ischemic optic neuropathy. Secondary goals are to evaluate if such treatment reduces the
progression or improves recovery of patients who are randomly assigned to treatment versus
standard of care.
Reports of Suspected Timoptic (Timolol Ophthalmic) Side Effects
Drug Hypersensitivity (4),
Intraocular Pressure Increased (3),
Ocular Hyperaemia (3),
Blindness Unilateral (2),
Cataract (2),
Oesophageal Carcinoma (2),
Intraocular Pressure Fluctuation (2),
Visual Impairment (2),
Bradycardia (2),
Blindness (2), more >>
|
